Drug details

Hulio (adalimumab-fkjp njection)

type of DMARDs, TNF Inhibitors, Monoclonal Antibodies

Hulio (adalimumab-fkjp) is a tumor necrosis factor (TNF) blocker used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis, and plaque psoriasis.

The drug is often used to treat Ankylosing spondylitis , Arthritis , Psoriatic arthritis , Ulcerative colitis .

This drug may have the following side effects:

• hives,
• difficulty breathing,
• swelling of your face, lips, tongue, or throat,
• dark urine,
• rash,
• vomiting,
• fever,
• easy bruising,
• unusual bleeding,
• pale skin,
• shortness of breath,
• weight loss,
• chills,
• tiredness,
• muscle aches,
• cough,
• irregular heartbeat,
• stomach pain
• sudden weight gain,
• swelling in the legs, ankles, or feet,
• yellowing of skin or eyes (jaundice), and

The following drugs are related to Hulio, either as a replacement or used together:

• Orencia (abatacept)
• Actemra (tocilizumab injection)
• Kineret (anakinra)
• Cimzia (certolizumab pegol injection)
• Combunox (oxycodone hcl and ibuprofen)
• Enbrel (etanercept)
• Vicoprofen (hydrocodone and ibuprofen)
• Remicade (infliximab)
• Trexall (methotrexate)
• Rituxan (rituximab)
• Rituxan Hycela (rituximab and hyaluronidase human injection)
• Xeljanz (tofacitinib tablets)